Span­ish VC preps launch for €100M fund with an em­pha­sis on ad­vanced ther­a­pies

In­vi­vo is tar­get­ing €100 mil­lion ($108.7 mil­lion) for its third fund, with an eye on Eu­ro­pean ear­ly-stage biotechs with ad­vanced ther­a­pies such as cell ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER